Remove Containment Remove Protein Remove Trials
article thumbnail

Pfizer takes COVID jab with ‘enhanced’ spike protein into phase 2

pharmaphorum

Pfizer and BioNTech have started a mid-stage trial of a new version of the COVID-19 vaccine based on a version of the spike protein that they hope will offer greater and broader protection against SARS-CoV-2 variants. The post Pfizer takes COVID jab with ‘enhanced’ spike protein into phase 2 appeared first on.

Protein 122
article thumbnail

Latest Data from Novavax COVID-19 Vaccine Trial Involving B.1.351 Variant Shared by Protein Vaccine Maker

XTalks

As Novavax awaits emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for its protein-based COVID-19 vaccine NVX-CoV2373, the company shared new data this week on the vaccine’s efficacy against the South African B.1.351 These results came from data from Novavax’s Phase III UK trial where B.1.117

Protein 97
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

No drugs for prions: could new approaches alleviate therapeutic scarcity?

Pharmaceutical Technology

As per the prevailing prion theory, a misfolded version of a normal cell-surface protein acts as the chief infectious agent. According to GlobalData’s Pharma Intelligence Center, there are only six drugs in active development for CJD, of which only one has been in clinical trials. And then comes the question of the right target.

Drugs 299
article thumbnail

AZ resumes UK coronavirus vaccine trial

pharmaphorum

AstraZeneca has resumed UK trials for its coronavirus vaccine, after the country’s medicines regulator gave the all-clear following a safety scare. A UK safety committee has concluded its investigations and recommended to the country’s Medicines and Healthcare products Regulatory Agency (MHRA) that trials are safe to resume.

Vaccine 104
article thumbnail

Flow cytometry: advantages in immunotherapy clinical trials

Pharmaceutical Technology

Patients provide blood samples for clinical trial sponsors to develop and deliver these emerging immunotherapies. A central lab with a global footprint provides both the efficient transportation arrangement and scientific rigor required to unlock the valuable information contained within patients’ biological samples.

article thumbnail

CSL doses first patient with haemophilia B gene therapy Hemgenix

Pharmaceutical Technology

This followed positive results from CSL’s Phase III HOPE-B trial (NCT03569891). Hemgenix works by dosing a patient with an engineered adeno-associated virus (AAV), containing the gene responsible for producing a protein called factor IX.

article thumbnail

Biologic Therapeutics Development, Part 1: Definition and Distinct Characteristics

Camargo

Like with small molecules, clinical trials of biologics are designed to determine pharmacokinetics (PK), pharmacodynamics (PD), safety, and efficacy. Essentially, a biologic is a product that is produced from living organisms or that contains components of living organisms. Recombinant therapeutic proteins. Fusion proteins.